Affordable Access

deepdyve-link
Publisher Website

Survival benefit with erlotinib maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC) according to response to first-line chemotherapy.

Authors
  • Coudert, B
  • Ciuleanu, T
  • Park, K
  • Wu, Y-L
  • Giaccone, G
  • Brugger, W
  • Gopalakrishna, P
  • Cappuzzo, F
Type
Published Article
Journal
Annals of Oncology
Publisher
Oxford University Press
Publication Date
Feb 01, 2012
Volume
23
Issue
2
Pages
388–394
Identifiers
DOI: 10.1093/annonc/mdr125
PMID: 21610154
Source
Medline
License
Unknown

Abstract

Patients with advanced NSCLC and SD following first-line platinum-based doublet chemotherapy derive a significant OS benefit from maintenance erlotinib therapy.

Report this publication

Statistics

Seen <100 times